Implementation of the FDA Accelerated Approval pathway raises questions

15 August 2017
fda_big

Questions about the US Food and Drug Administration’s Accelerated Approval pathway are revealed today (August 15) in a study published in the Journal of the American Medical Association (JAMA).

Researchers from the London School of Economics and Political Science (LSE) and Brigham and Women’s Hospital/Harvard Medical School studied the clinical trials used by the FDA to authorise and confirm drugs via the Accelerated Approval between 2009 and 2013. They found that at least three years after being fast-tracked to market – and in some cases seven years and counting – half of the drugs had still not had the required post-approval studies completed. In most cases, the reasons behind these delays were not publicly available.

The Accelerated Approval pathway allows the FDA to expedite the approval of drugs treating serious illnesses or addressing unmet medical need on the basis of so-called surrogate measures – laboratory measurement, radiographic images, physical signs or other measures – that may not be strongly tied to actual patient clinical benefit. Once approved, these drugs must then undergo further clinical studies to determine whether the suggested benefits translate into real-life clinical improvements. If these studies fail to demonstrate clinical benefit, the FDA may withdraw the drug from market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical